Kisspeptin-10 is the C-terminal decapeptide of the peptide products encoded by the human KISS1 gene, with the sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe and a C-terminal carboxamide rather than a free acid. In the residue numbering of the 54-residue parent peptide it spans positions 45-54, which is why much of the older literature calls the same molecule metastin(45-54) [3, 6]. The terminal Arg-Phe-amide places it in the RFamide family of signaling peptides, and that amidated C-terminus is the part the receptor reads: every KISS1-derived peptide identified as a high-potency agonist in the original deorphanization work shared it [1, 2].

Identity and characterization

Echo Peptides publishes a verified identity block for this compound, and the guide uses the same figures rather than restating them from a different source:

Two things in that formula are worth reading rather than skimming. The nitrogen count of 17 is one higher than the decapeptide's backbone and side chains account for on their own — ten backbone nitrogens, two from the asparagine side chains, one from tryptophan, three from arginine — and the extra nitrogen is the C-terminal amide. The oxygen count of 14 is likewise the count for an amidated peptide, not for a free acid. A des-amido preparation of the same sequence would differ by roughly one mass unit and would not be expected to behave equivalently in a binding assay — though no study cited here tested the free acid directly — because every KISS1-derived peptide reported as a high-potency agonist in the deorphanization work carried an amidated C-terminus [1, 2]. Any identity check on incoming material is worth reading with the amide in mind, not just the nominal mass.

Kisspeptin-10 is not the only kisspeptin. Proteolytic processing of the KISS1 product yields 54-, 14- and 13-residue peptides that all terminate in the same ten residues [1, 5]. That shared C-terminus is why kisspeptin-10 behaves as the minimal well-characterized member of the family, and also why results obtained with it should not be read as measurements of what any single endogenous kisspeptin does.

Mechanism as studied

Kisspeptin-10's receptor is the G protein-coupled receptor variously named GPR54, KISS1R, AXOR12 and hOT7T175 in different papers. Two independent 2001 reports established the pairing. Kotani and colleagues isolated agonist peptides for the then-orphan GPR54 from human placenta, showed they derived from the KISS1 product, and reported that they bound rat and human GPR54 expressed in Chinese hamster ovary K1 cells with low nanomolar affinities [1]. In parallel, Muir and colleagues cloned AXOR12 from a human brain cDNA library, identified surrogate agonist peptides sharing a common C-terminal amidated motif, and found that KISS1-derived peptides gave the high-potency agonism expected of a cognate ligand [2].

What the receptor does when it is occupied

In the recombinant CHO-K1 system, kisspeptins stimulated PIP₂ hydrolysis, Ca²⁺ mobilization, arachidonic acid release, phosphorylation of ERK1/2 and p38 MAP kinase, and stress fiber formation, while inhibiting cell proliferation [1]. That set of readouts is the signature of Gαq/11 coupling through phospholipase C, and downstream inositol phosphate accumulation has since become the standard functional readout for the receptor. Kuohung and colleagues built exactly that assay for screening — a homogeneous time-resolved fluorescence measurement of inositol phosphate accumulation in CHO cells stably expressing human GPR54 — and used it against a 110,000-compound library, noting that at the time no small-molecule modulators of GPR54 existed for experimental use [11].

Which residues matter

Truncation studies place the active pharmacophore firmly at the C-terminus. Tomita and colleagues state that the short-chain C-terminal decapeptide amide, metastin(45-54), exerts the same bioactivities as full-length metastin, and their structure-activity work on C-terminal pentapeptide-based analogs produced H-Amb-Nal(2)-Gly-Leu-Arg-Trp-NH₂, which they reported as the most potent GPR54 agonist described up to that point [3]. The practical reading is that the N-terminal half of kisspeptin-10 is largely dispensable for receptor activation, and that a five-residue scaffold is enough to build on.

Desensitization and receptor trafficking

Occupancy is not the whole story, because the receptor regulates itself. Working in HEK293 cells, Pampillo and colleagues reported that GPR54 exhibits constitutive activity, internalizes, and associates with GPCR kinase 2 (GRK2) and with β-arrestin-1 and -2 through sequences in its second intracellular loop and cytoplasmic tail; GRK2 stimulated desensitization of the receptor, and in a breast-carcinoma-derived MDA MB-231 line engineered to express about 75% less β-arrestin-2, β-arrestin-2 mediated receptor activation of ERK1/2 [7]. Millar and Babwah's review draws the balance out: an active surface population of KISS1R is maintained by the interplay of rapid desensitization, internalization and recycling of resensitized receptor, and the extent of desensitization observed across human, domestic and laboratory animal studies depends on ligand efficacy and concentration and on the physiological, developmental and metabolic status of the organism [8]. Any protocol with sustained or repeated exposure is measuring that regulatory machinery as much as it is measuring the ligand.

Model systems it has actually been examined in

Recombinant expression systems. CHO-K1 and HEK293 cells carrying rat or human receptor account for most of the quantitative binding and signaling data [1, 7, 11]. These are the systems in which affinity and coupling have been measured, and they are the systems in which the receptor's constitutive activity was characterized [7].

Hypothalamic neurons and the GT1-7 line. Quaynor and colleagues amplified RNA from individually identified hypothalamic GnRH neurons and detected transcripts for GnRH, kisspeptin-1 and GPR54 in the same cells; bioluminescence resonance energy transfer between tagged GnRH receptor and GPR54 co-expressed in HEK293 cells indicated hetero-oligomerization of the two receptors; whole-cell patch-clamp recordings from identified GnRH neurons showed an initial depolarizing effect of kisspeptin on membrane potential followed by increased action potential firing; and in perifusion, treating GT1-7 neuronal cells with kisspeptin-10 increased GnRH peak amplitude and duration [9]. This is the cleanest cellular demonstration that the decapeptide acts on the neurons that sit at the top of the reproductive axis, and it is a measurement of membrane potential, firing rate and secretory profile in culture — not of anything in an intact animal.

Placental trophoblast-derived cells. Roseweir and colleagues found that HTR8SVneo cells, a line derived from first-trimester extravillous trophoblasts, specifically bound ¹²⁵I-kisspeptin-10 — but that kisspeptin-10 did not induce inositol phosphate production in them. Migration was nevertheless inhibited, with maximal inhibition at 100 nM, and the signaling that accompanied it ran through Ser9 phosphorylation of GSK3β (a three-fold increase at 5 minutes), transient ERK1/2 and p38 MAPK phosphorylation peaking at 10 minutes, and Tyr925 phosphorylation of FAK (three-fold at 10 minutes) [10]. The dissociation matters: the same ligand that drives inositol phosphate turnover in a recombinant CHO background produced no measurable inositol phosphate signal here while still altering cell behavior. Receptor coupling in this system is a property of the cell, not a fixed property of the peptide.

Analog chemistry. Kisspeptin-10 also appears as the reference compound against which modified peptides are scored — the pentapeptide agonists of Tomita and colleagues [3] and the MMP-resistant phosphinic peptides of Zhang and colleagues [5], where one isomer showed both receptor-agonist activity and inhibition of MMP-2.

What the evidence does not establish

Everything summarized above is a molecular or cellular measurement: binding affinity in a transfected line, a second-messenger readout, a phosphorylation time course, a membrane potential trace, a migration assay. None of it establishes an outcome in an intact organism, and this guide makes no such claim. Some of the cited papers do also contain whole-animal work; none of that work is summarized here, and nothing below should be read as a statement about a living animal.

Three further limits are worth stating explicitly.

  • The receptor is not confined to one tissue. The tissue surveys published alongside the deorphanization reports found the receptor at high levels in placenta, pituitary, pancreas and spinal cord, and receptor mRNA highest in brain, pituitary and placenta [1, 2]. An experiment that treats kisspeptin-10 as a hypothalamus-selective input is assuming a selectivity the expression data does not support.
  • Coupling is inconsistent between systems. Specific binding without detectable inositol phosphate production has been reported in at least one human cell line [10], while the same pathway is the standard readout in CHO cells [1, 11]. There is no single potency figure that carries across assay formats, and quoting one as if there were would misrepresent the literature.
  • Desensitization is a variable, not a constant. Its magnitude is explicitly reported to depend on ligand efficacy and concentration and on the status of the organism or preparation [8], which means results from sustained-exposure designs are not comparable across laboratories without matching those conditions.

Handling and stability

The literature is unusually specific about how this peptide is destroyed, and unusually quiet about how to keep it intact.

The destruction pathway is proteolytic and well mapped. Takino and colleagues showed that active MMP-2, MMP-9, MT1-MMP, MT3-MMP and MT5-MMP cleave a Gly-Leu peptide bond in both the full-length KISS1 protein and the metastin decapeptide, and that digestion of the decapeptide by MMP abolished its ligand activity [4]. Zhang and colleagues place the same scission in the numbering of the 54-residue parent — between Gly51 and Leu52, which are the seventh and eighth residues of kisspeptin-10 itself — and describe cleavage there as the route by which all the native functional human kisspeptins are rapidly inactivated by MMPs [5]. Practically, any matrix carrying metalloproteinase activity is a degradation route: conditioned medium from an MMP-expressing line, serum-containing medium, tissue or cell lysate.

Non-enzymatic instability has been quantified too, in one matrix. Using a validated LC-MS/MS assay with a 0.5 ng/mL lower limit of quantitation, Liu and colleagues measured decomposition half-lives for kisspeptin-10 in rat plasma of 6.8 minutes at 4 °C, 2.9 minutes at 25 °C and 1.7 minutes at 37 °C, and characterized the principal decomposition product as the N-terminally truncated peptide lacking the tyrosine at position 45 [6]. Those numbers describe rat plasma. They are not measurements of the lyophilized solid, of a simple aqueous buffer, or of a stock held frozen, and they should not be quoted as if they were.

That is the honest boundary of what can be sourced. The primary literature cited here contains no characterization of the dry powder's shelf life, no freeze-thaw stability series, no data on adsorption to polypropylene or glass, and no comparison of buffer compositions or pH for reconstituted stock. Storage conditions for research material — the refrigerated, lyophilized state in which this compound is supplied — rest on general peptide-handling practice, not on any of the papers above. Laboratories that need those figures for their own buffer and workflow have to generate them, and an assay with a defined lower limit of quantitation of the kind used in [6] is the obvious way to do it.

Open questions

The gaps in this literature are specific enough to be worth naming.

  • Why does specific binding occur without measurable inositol phosphate production in a trophoblast-derived line while driving it in CHO cells [1, 10]? Roseweir and colleagues suggest that EGF-receptor transactivation feeds the ERK1/2 phosphorylation they measured, and report that the signaling events were differentially blocked by a panel of inhibitors that included one against Gq/11 [10] — yet no inositol phosphate production was detectable in that line. How a Gq/11-sensitive pathway runs without a measurable inositol phosphate signal there is unresolved.
  • Can the β-arrestin arm be separated from the Gαq/11 arm by ligand design? β-arrestin-2 mediates receptor-driven ERK1/2 activation in at least one cell background [7], and the review literature identifies the Gαq/11- and β-arrestin-dependent arms as the pathways whose understanding will aid the development of analogs modulating KISS1R signaling [8], without reporting a ligand that separates them.
  • Do MMP-resistant analogs retain full agonism? One phosphinic isomer combined receptor-agonist activity with MMP-2 inhibition, but it is reported as a single lead compound, not a validated tool [5].
  • Does the minimal pentapeptide pharmacophore [3] behave like the decapeptide in the cellular systems where the decapeptide has been characterized? The potency comparison was made in a receptor-activation assay, not across the range of readouts in [9] and [10].
  • How much of the baseline signal in overexpression systems is the receptor's own constitutive activity [7], and how should that be subtracted when comparing agonist potencies between laboratories?

Kisspeptin-10 is a well-defined molecule with an unusually clear structure-activity story and an unusually short life in biological matrices. Both facts should shape how it is used at the bench: identity is easy to confirm and hard to fake, and integrity is easy to lose between the vial and the assay plate.